The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Orelabrutinib in Chinese Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Updated Results of a Multicenter, Phase I/IIa Trial

被引：0
|
作者：
Shi, Yuankai [1 ]
Qin, Yan [1 ]
Zang, Aimin [2 ]
Li, Yufu [3 ]
Yang, Yanli [4 ]
Hui Liu [5 ]
Gao, Sujun [6 ]
Wang, Xinghe [7 ]
Zhang, Weijing [7 ]
Jin, Zhengming [8 ]
Hui Zhou [9 ]
Wang Hua-Qing [10 ]
Min Wei [11 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China
[2] Hebei Med Univ, Affiliate Hosp, Dept Oncol, Baoding, Peoples R China
[3] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China
[4] Bengbu Med Coll, Affiliated Hosp 1, Bengbu, Peoples R China
[5] Beijing Hosp, Dept Hematol, Beijing, Peoples R China
[6] First Hosp Jilin Univ, Dept Hematol, Changchun, Peoples R China
[7] Capital Med Univ, Beijing Shijitan Hosp, Beijing, Peoples R China
[8] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China
[9] Cent South Univ, Affiliated Tumor Hosp, Xiangya Med Sch, Hunan Canc Hosp,Dept Lymphoma & Hematol, Changsha, Peoples R China
[10] Tianjin Peoples Hosp, Dept Oncol, Tianjin, Peoples R China
[11] Beijing Mabworks Biotech Co Ltd, Med Dept, Beijing, Peoples R China
来源：
BLOOD | 2022年 / 140卷
关键词：
MIL62; type II anti-CD20 monoclonal antibody; r/r B-NHL; DLBCL;
D O I：
10.1182/blood-2022-162984
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：9482 / 9483
页数：2
相关论文
共 50 条
  • [21] Maintenance therapy using the anti-CD20 antibody Rituximab in patients with B-cell non-Hodgkin lymphoma
    Neumann, F
    Martin, S
    Kronenwett, R
    Fischer, C
    Kondakci, M
    Kobbe, G
    Gattermann, N
    Haas, R
    [J]. BLOOD, 2003, 102 (11) : 298B - 298B
  • [22] Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma; Results of a Phase II Trial
    Kolibaba, Kathryn
    Burke, John M.
    Brooks, Heather D.
    Mahadevan, Daruka
    Melear, Jason
    Farber, Charles M.
    Fanning, Suzanne R.
    Schreeder, Marshall T.
    Boccia, Ralph V.
    Sportelli, Peter
    Miskin, Hari P.
    Weiss, Michael S.
    Sharman, Jeff P.
    [J]. BLOOD, 2015, 126 (23)
  • [23] THE TYPE. ANTI-CD20MONOCLONAL ANTIBODY MIL62 OR CYCLOSPORINE IN CHINESE PRIMARY MEMBRANOUS NEPHROPATHY: PRELIMINARY RESULTS OF A PHASE IB/II TRIAL
    Cui, Zhao
    Zhang, Yimiao
    Li, Heng
    Zhou, Hua
    Lin, Hongli
    Xing, Guangqun
    Chen, Wei
    Liang, Wei
    Luo, Ping
    Chen, Xiaolan
    Xu, Hui
    Zha, Yan
    Wang, Yue
    Chen, Xing
    Ni, Zhaohui
    Zhang, Junjun
    Lu, Wanhong
    Zhang, Haitao
    Long, Haibo
    Sun, Dong
    Cao, Yu
    Zhao, Minghui
    Meng, Song
    Wei, Min
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I393 - I394
  • [24] A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma
    Ohmachi, Ken
    Ogura, Michinori
    Suehiro, Youko
    Ando, Kiyoshi
    Uchida, Toshiki
    Choi, Ilseung
    Ogawa, Yoshiaki
    Kobayashi, Miki
    Fukino, Koichi
    Yokoi, Yuki
    Okamura, Jun
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (06) : 657 - 664
  • [25] A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma
    Ken Ohmachi
    Michinori Ogura
    Youko Suehiro
    Kiyoshi Ando
    Toshiki Uchida
    Ilseung Choi
    Yoshiaki Ogawa
    Miki Kobayashi
    Koichi Fukino
    Yuki Yokoi
    Jun Okamura
    [J]. International Journal of Hematology, 2019, 109 : 657 - 664
  • [26] Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
    Morschhauser, F.
    Marlton, P.
    Vitolo, U.
    Linden, O.
    Seymour, J. F.
    Crump, M.
    Coiffier, B.
    Foa, R.
    Wassner, E.
    Burger, H. -U.
    Brennan, B.
    Mendila, M.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 (09) : 1870 - 1876
  • [27] UPDATED RESULTS OF A PHASE-I TRIAL OF 131-I-ANTI-B1 (ANTI-CD20) RADIOIMMUNOTHERAPY (RIT) FOR REFRACTORY B-CELL LYMPHOMA
    KAMINSKI, MS
    ZASADNY, KR
    MILIK, AW
    ROSS, CW
    FRANCIS, IR
    BURGESS, J
    CRAWFORD, S
    ESTES, J
    HODUL, P
    COOK, R
    REGAN, D
    PETRY, N
    GLENN, S
    BUTCHKO, G
    WAHL, RL
    [J]. BLOOD, 1993, 82 (10) : A332 - A332
  • [28] Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma
    Godfrey, James
    Mei, Matthew
    Chen, Lu
    Song, Joo Y.
    Bedell, Victoria
    Budde, L. Elizabeth
    Armenian, Saro
    Puverel, Sandrine
    Nikolaenko, Liana
    Chen, Robert
    Daniels, Shari
    Kennedy, Neena
    Peters, Lacolle
    Rosen, Steven T.
    Forman, Stephen J.
    Popplewell, Leslie L.
    Kwak, Larry W.
    Herrera, Alex F.
    [J]. REVISTA CHILENA DE LITERATURA, 2024, (109): : 533 - 542
  • [29] Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma
    Godfrey, James
    Mei, Matthew
    Chen, Lu
    Song, Joo Y.
    Bedell, Victoria
    Budde, L. Elizabeth
    Armenian, Saro
    Puverel, Sandrine
    Nikolaenko, Liana
    Chen, Robert
    Daniels, Shari
    Kennedy, Neena
    Peters, Lacolle
    Rosen, Steven T.
    Forman, Stephen J.
    Popplewell, Leslie L.
    Kwak, Larry W.
    Herrera, Alex F.
    [J]. HAEMATOLOGICA, 2024, 109 (02) : 533 - 542
  • [30] Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
    Jurczak, W.
    Zinzani, P. L.
    Gaidano, G.
    Goy, A.
    Provencio, M.
    Nagy, Z.
    Robak, T.
    Maddocks, K.
    Buske, C.
    Ambarkhane, S.
    Winderlich, M.
    Dirnberger-Hertweck, M.
    Korolkiewicz, R.
    Blum, K. A.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (05) : 1266 - 1272
12345